We investigated an association between pulmonary function testing (PFT) before bone marrow transplantation and the development of severe veno-occlusive disease (VOD) of the liver. We previously noted that reductions in diffusing capacity of the lung for carbon monoxide (corrected for hemoglobin) (D L CO c ) were associated with mortality after transplantation, but this was not caused by respiratory failure. We performed a case-series review of prospectively collected data from 307 marrow recipients who underwent PFT within 2 weeks of transplantation. Of these, 170 (56%) developed VOD; 39 (13%) mild, 81 (26%) moderate, and 50 (16%) severe or fatal. Both total lung capacity (TLC) and D L CO c were associated with severe VOD in univariate analysis (P = 0.006 for each). However, D L CO c entered logistic regression models that contained variables for all known risk factors for severe VOD, while TLC did not contribute additional predictive information. The odds ratio (OR) associated with a D L CO c below the lower limits of normal (70% of predicted) was 2.4 (95% CI, 1.0 to 5.4; P = 0.04). We conclude that reduced diffusion capacity of the lung measured before marrow transplantation is an independent risk for severe hepatic VOD. We speculate that the decreased D L CO c indicates pre-existing systemic endothelial cell damage and a susceptibility to severe hepatic injury from chemotherapy. Keywords: bone marrow transplantation; hepatic venoocclusive disease; pulmonary function tests; diffusing capacity; risk factors Pulmonary function testing (PFT) is frequently performed before marrow transplantation.
tation are associated with an increased risk of death during the first 6 months after transplantation. Surprisingly, the D L CO c and the P(A-a)O 2 acted independently of each other as risk factors, suggesting that they indicate separate mechanisms leading to death. 9 Furthermore, the increased incidence of death associated with a reduced D L CO c could not be accounted for by an increase in the incidence of respiratory failure.
We therefore hypothesized that a reduced D L CO c may be associated with another common organ failure leading to death after marrow transplantation, such as severe venoocclusive disease (VOD) of the liver. We postulated that a decreased D L CO c measurement, which is influenced by capillary blood volume in the lung, could reflect systemic endothelial damage due to previous chemotherapy or irradiation. Therefore, the increased mortality associated with low D L CO c may be due to non-pulmonary complications related to further endothelial injury during the cytoreductive conditioning chemotherapy.
Since VOD of the liver has been associated with such injury 10, 11 we designed the present study to determine whether an association exists between pretransplant D L CO c and development of severe VOD after bone marrow transplantation. Ideally, we wanted to analyze a data set that contained indicator variables not only for the PFT results and for VOD of the liver, but also for each of the known risk factors for severe VOD of the liver. Fortunately, a previously published study involving such a cohort exists at our center. 12 To our knowledge, this is the only such database available.
Patients and methods

Patients
All 360 patients who received chemotherapy and/or irradiation in preparation for marrow transplantation at the Fred Hutchinson Cancer Research Center between August 1987 and August 1988 were eligible. These patients had been subjects of a detailed, prospective evaluation of the risk factors for VOD by McDonald et al. 12 Five patients who died before marrow infusion were excluded from the analysis, as were 48 patients who did not perform PFT within 2 weeks before marrow transplantation. The remaining 307 patients had at least one PFT variable result available: spirometry (FEV 1 and FVC), total lung capacity (TLC), D L CO c , or arterial blood gas (ABG). These patients represent 86% of all marrow transplants performed at our institution during this period. This cohort is also included in a previous study demonstrating the predictive value of pretransplant PFT results for mortality after marrow transplantation. 9 
PFT methods
The tests were performed and interpreted according to American Thoracic Society guidelines. 13 Lung volumes were determined by the nitrogen washout technique using a pulmonary function analyzer (Gould 1000 IV; Gould Inc, Dayton, OH, USA). The diffusing capacity for carbon monoxide was tested by single breath technique and corrected for hemoglobin content (D L CO c ). Results for TLC and D L CO c were compared to published normal values and reported as percentages. 13, 14 The FEV 1 /FVC ratio was used as a measure of airflow obstruction and values greater or equal to 80% were considered normal for any age. Samples for arterial blood gases were obtained by puncture of the radial artery with the patient in the sitting position and breathing room air. The alveolar-arterial PO 2 difference (P(A-a)O 2 ) was calculated using the alveolar gas equation and assuming a respiratory ratio of 0.8.
Definitions
VOD was defined according to the criteria of McDonald 12 as the occurrence of two of the following three events within 20 days of transplantation: hyperbilirubinemia (total serum bilirubin Ͼ2 mg/dl), hepatomegaly or right upper quadrant pain of liver origin, and sudden weight gain (Ͼ2% of baseline body weight) in the absence of any other explanation for these signs and symptoms. VOD was classified as 'mild' if patients showed no apparent adverse effect from liver disease, required no medications for diuresis of excessive fluid or for hepatic pain, and had completely reversible signs, symptoms and laboratory abnormalities; 'moderate' if patients had an adverse effect from liver disease, required sodium restriction and diuretics for volume excess or medication to alleviate the pain from hepatomegaly, and eventually showed a complete resolution of all signs of liver damage; 'severe' if there was either no resolution of signs, symptoms and laboratory values of liver disease before day 100 or death of the patient. Patients were classified as having 'liver disease of uncertain cause' if they developed both mild hyperbilirubinemia (total serum bilirubin Ͻ2 mg/dl) and weight gain below 2%, if their liver disease could be explained by graft-versus-host disease (GVHD), sepsis syndrome (fever and hypotension), cardiac failure or tumor infiltration; or if they died before day 5 after transplantation. Patients who showed no liver abnormalities within 20 days of marrow infusion were classified as having 'no liver disease'.
Marrow transplantation
Marrow transplantation was performed according to published protocols. [15] [16] [17] [18] Patients received autologous, syngeneic or allogeneic bone marrow. Allogeneic transplants were HLA-identical or nonidentical, the latter being mismatched at one to three antigens at the HLA A, B or D loci on the unshared haplotype. 18, 19 The day of marrow infusion is referred to as 'day zero'. Conditioning regimens have been reported. 18, 20, 21 Patients receiving allogeneic transplantation had GVHD prophylaxis with combinations of methotrexate, cyclosporine and methylprednisolone. 17 Patients not allergic to sulfa drugs received trimethoprimsulfamethoxazole as prophylaxis for Pneumocystis carinii pneumonia. 22 
Statistical analysis
All clinical data were collected in a prospective fashion and reviewed retrospectively for the present study. Initial univariate analyses of associations between the PFT variables and severe VOD were performed using the Wilcoxon rank sums method. Multivariate analyses were performed by stepwise logistic regression method. Cases with missing values were excluded from the logistic regression analyses, as were cases in which the diagnosis of hepatic VOD was 'uncertain'. Variables required a significance level of 0.25 to enter the regression models, and a level of 0.15 to remain in stepwise analyses. The PFT results (FEV 1 /FVC, TLC, D L CO c and P(A-a)O 2 ) were treated as continuous variables for initial univariate and logistic regression analyses. Then, TLC and D L CO c were treated as dichotomous variables in additional logistic regression analyses, and in Chi-square analyses of associations between TLC and D L CO c . All statistical analyses were performed using SAS software.
Results
Of the 307 patients, 170 developed VOD of the liver (56%); 39 patients had mild VOD (13%), 81 had moderate VOD (26%), and 50 had severe VOD (16%). No VOD was noted in 71 patients (23%) and the diagnosis was 'liver disease of uncertain cause' in 66 (21%). The results of the PFT before marrow transplantation are presented in Table 1 .
The 53 patients that had been excluded from the analyses did not have PFT results available within 2 weeks before transplantation. The mean age of those without PFT results was 13.8 ± 14.5 years (median 6.3, range 0.8-52.6). Thirtytwo (60%) of these were less than 8 years old and were judged unable to cooperate with testing. Two (4%) had PFT more than 2 weeks before transplantation, and the remainder were either too ill, had testing performed elsewhere, and/or died before infusion of the transplanted marrow. The incidence and severity of hepatic VOD was not significantly different from those who had PFT results available. We first tested the association of each of the PFT variables for the development of VOD of any grade. None of the variables was significantly associated (data not shown). We then tested the association between each PFT variable and the development of severe VOD by the Wilcoxon rank sums method. Both TLC and D L CO c were significantly associated with severe VOD (P = 0.006, each), whereas FEV 1 /FVC, and P(A-a)O 2 were not ( Table 2) .
The odds ratio (OR) of developing severe VOD associated with each of the PFT variables was calculated in stepwise logistic regression models. We calculated the OR for each 1% decine (as a percentage of the predicted value) and the OR associated with the lower limits of normal for the variable. Each 1% decrease in the D L CO c (as a percentage of the predicted value) had an OR of 1.023 (95% CI = 0.992, 1.055; P = 0.138). Patients with a D L CO c below 70% of predicted (the lower limits of normal in our center) had an OR of 2.78 (95% CI = 1.36, 5.67; P = 0.005). The OR associated with declines in TLC (as a percentage of predicted values) was 1.023 (95% CI = 0.989, 1.058; P = 0.183) for each 1% decrease, and the OR associated with a TLC below 80% of predicted (the lower limits of normal) was 2.26 (95% CI = 1.09, 4.96; P = 0.029). Other PFT variables did not enter the model at the 0.25 significance level.
Several pretransplant variables are known to be predictors of severe VOD: elevated serum aminotransferase levels (ALT, AST) before transplantation, use of acyclovir before cytoreductive therapy, use of vancomycin during cytoreductive therapy, high-dose conditioning regimen, mis- Table 2 Associations between pulmonary function testing variables and hepatic veno-occlusive disease (VOD) matched or unrelated marrow donor, and prior irradiation treatment to the abdomen. 12 These variables had been shown to be independently associated with severe VOD in this same cohort of patients by McDonald et al. 12 We wanted to know whether PFT results contributed additional predictive information to that provided by these covariates. We modeled the six known predictor variables in a forward stepping multivariate logistic regression. We then entered the PFT variables into the model in a stepwise fashion. D L CO c entered the model, with an OR of 1.027 (95% CI = 1.003, 1.052; P = 0.027) for each 1% decline, while TLC did not add further predictive information. In similar models, the OR associated with a D L CO c below 70% of predicted was 2.4 (95% CI = 1.05, 5.44; P = 0.038) ( Table 3 ). The addition of the D L CO c significantly improved the fit of the model by the likelihood ratio test (P = 0.024). Several of the variables previously noted to be independently associated with severe VOD no longer reached statistical significance (P Ͻ 0.05) in the regression model that contained D L CO c . Only D L CO c , elevated serum aminotransferase levels before transplantation, use of vancomycin during cytoreductive therapy, and high-dose conditioning regimen remained significant in the analysis.
We then examined whether there was a specific value of the D L CO c that identified patients at the highest risk for severe VOD. To examine the possibility of a linear relationship we tested the association between the severity of VOD and the value of D L CO c by analysis of variance (ANOVA). There was a statistically significant decrease in the mean value for D L CO c associated with increasing severity of VOD (P = 0.034). The mean D L CO c (as a percentage of predicted) was 80.3% for patients who did not develop any VOD and was 72.2% for those who developed severe VOD. Lastly, we examined the incidence of severe hepatic VOD associated with various levels of D L CO c (as a percentage of predicted) before transplantation. Figure 1 presents the incidence of severe VOD for each 5% range of D L CO c . The incidence increased for values of D L CO c below 65% of predicted. The incidence of severe hepatic VOD associa- ted with a D L CO c below 65% of predicted was 36.4%, compared to 11.9% associated with a D L CO c greater than 65% of predicted (P = 0.001).
Discussion
PFT results before marrow transplantation are associated with the risk of both respiratory complications and death after transplant in several studies. [1] [2] [3] [4] [5] [6] [7] [8] [9] Most studies have focused on measures of airflow (FEV 1 and FVC) as predictors of pneumonia. At this center, D L CO c and P(A-a)O 2 were independently associated with death when entered in a multivariate proportional hazards model controlling for other covariates associated with mortality after transplant, such as age, HLA-nonidentical donor marrow, active malignancy at transplant, and primary diagnosis. 9 That study, demonstrating the association of D L CO c and P(A-a)O 2 with death, included patients evaluated in this present study. That study differed from others by evaluating death, rather than pneumonia, as the primary endpoint, and by controlling for competing covariates. Lung volume, as measured by TLC, was associated with death in that study, but did not contain predictive information beyond that associated with the D L CO c . These findings support and expand upon the predictive value of FEV 1 and FVC for pneumonia found in other studies.
The mechanisms of death associated with the PFT variables are unclear. Most of the deaths associated with abnormal PFT results occur within months of the marrow transplant. 9 It was reasonable to assume that abnormal lung function predicted a risk of respiratory failure. Supporting this assumption Horak et al 7 noted an association between FEV 1 before transplantation and subsequent cytomegalovirus pneumonia. However, D L CO c and P(A-a)O 2 , which are physiologically associated, were found to be independent and additive risks for mortality at our center. 9 These findings suggest that these PFT variables are related to distinct mechanisms of death. Furthermore, the risk of death associated with reduced D L CO c was not accounted for by inclusion of a variable for respiratory failure in the proportional hazards model. 9 In contrast, the risk of death associated with an increase in P(A-a)O 2 was accounted for by respiratory failure in similar models. The cause (or causes) of death associated with D L CO c were not identified. However, in contrast to P(A-a)O 2 , respiratory failure does not appear to play a major role.
VOD of the liver is one of the major causes of nonpulmonary mortality after marrow transplantation. 23, 24 The proposed precipitating event is sinusoidal endothelial cell injury during high-dose chemotherapy. [24] [25] [26] Since reductions in D L CO c can be induced by previous chemotherapy and/or irradiation, 4 we hypothesized that reduced D L CO c may represent generalized endothelial injury. Thus, the D L CO c would present a risk for fatal toxicity to nonpulmonary organs due to subsequent injury during the chemotherapy preparation for marrow transplantation. Specifically, we proposed that reduced D L CO c before marrow transplantation was associated with severe hepatic VOD.
To study the relationship of D L CO c and hepatic VOD we required a cohort with data regarding the incidence, severity and risk factors for VOD. We chose this present cohort because it had been the previous subject of a detailed prospective evaluation of the incidence, severity, and risk factors of hepatic VOD. 12 To our knowledge there is no other cohort that contains such extensive data about the severity of VOD and has prospectively collected risk factor information. In addition, this cohort was included in that examined for an association between pre-transplant PFT and mortality. 9 The finding of an association between the D L CO c and severe VOD in this cohort supports the validity of the PFT result as a risk for mortality after marrow transplantation.
The relationship between TLC and hepatic VOD was complex. There was a statistically significant association between reduced TLC and D L CO c in our study (data not shown). Almost all patients with reduced TLC also had reduced D L CO c . However, 21% of the patients with a low D L CO c had a normal TLC. In logistic regression analyses, D L CO c appeared to contain more predictive information than TLC, and entered the models with all other covariates associated with hepatic VOD present. Thus, the TLC value added no additional information if the D L CO c was known to be reduced. This finding suggests that although reduced TLC may indicate lung injury, D L CO c may be a more sensitive marker of systemic endothelial damage (or susceptibility to injury).
Pretransplant D L CO c may be decreased due to a number of factors. 4 Decreased alveolar surface associated with emphysema is a common cause of decreased D L CO c . However, we do not believe this was the cause in our patients since airflow obstruction was uncommon, and is not associated with mortality 9, 27 or severe hepatic VOD after transplantation. More likely, prior irradiation and/or cytotoxic chemotherapeutic agents caused both a restrictive lung defect and reduced D L CO c before marrow transplantation. It is reasonable to assume that these agents caused systemic vascular endothelial damage and an increased risk of severe VOD after additional insult due to the cytoreductive therapy for marrow transplantation.
Transplant-related insults in the setting of pre-existing pulmonary and hepatic injury contribute to hepatic VOD. In support of that hypothesis, elevated levels of transforming growth factor-beta after induction for breast cancer but prior to conditioning for marrow transplantation, have been associated with both hepatic fibrosis and idiopathic pneumonia. 28 Furthermore, Scrobohaci et al 29 noted that abnormalities of coagulation developed before the onset of hepatic VOD after transplantation among leukemia patients. These patients had received prior chemotherapy. However, patients with aplastic anemia who had not received prior chemotherapy did not develop these coagulation abnormalities or hepatic VOD.
We conclude that reduced D L CO c before marrow transplantation represents an increased risk for severe hepatic VOD. The D L CO c does not appear to predict the development of hepatic VOD, only the severity. These findings are consistent with a reduced D L CO c indicating pre-existing hepatic injury. Thus, if injury occurs during the preparation for transplantation, the physiological consequences are more pronounced. We expected that a reduced D L CO c before marrow transplantation would identify the same cohort of patients as those with elevated hepatic aminotransferase. Surprisingly, the risk associated with a reduced D L CO c was independent of other known risk factors for severe VOD. 12 In addition, the lack of association between P(A-a)O 2 and severe VOD was consistent with our previous finding that respiratory failure appeared to be involved in the deaths of patients with this marker of hypoxemia.
The D L CO c and elevated hepatic transaminases may be important biological markers of increased risk for severe hepatic VOD. All other known risks are demographic or historical in nature. After addition of D L CO c to the logistic regression model, three of the previously identified demographic risk factors no longer reached statistical significance; pretransplant acyclovir therapy, mismatched or unrelated donor marrow, and previous radiation therapy to the abdomen. Future studies of hepatic VOD should note D L CO c results and the levels of hepatic transaminases in the design and interpretation of results, as well as in the stratification of subjects.
The practical, clinical use of a reduced D L CO c before transplantation is problematic. The risk associated with the D L CO c appears to be linear, however a 'cut-off' value below 65-70% of predicted seems to indicate increased risk. For reference, we calculated the odds ratio associated with D L CO c of 70% of predicted to be 2.39 (95% CI = 1.05, 5.44; P = 0.038) ( Table 3 ). Thus, it may be difficult to use the value for D L CO c as an absolute exclusion criterion in the absence of other risk factors. Nonetheless, in conjunction with other known risk factors for mortality, an informed decision can be made about proceeding with transplantation. We believe that an important use of the pretransplant D L CO c results may be in selecting the most efficacious and least toxic preparative cytoreductive therapy before transplantation. It may have been assumed that patients with abnormal PFT results before transplant were at risk for pulmonary complications and should receive treatment associated with the least lung toxicity. However, the data regarding D L CO c and the risk for hepatic VOD suggest that the liver may be the organ we should be the most concerned about protecting from regimen-related toxicity.
